Evobrutinib PK in Renal Impairment

Phase 1, open-label trial of evobrutinib in multiple sclerosis (MS) (4 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 30 hours, Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity at 30 hours and 1 more. Started Mar 2018; status: completed.